RECORD IPO FOR KAILERA THERAPEUTICS
May 8, 2026
The GLP-1 effect continues to make investors' eyes shine, but Kailera Therapeutics may have something more by having targeted the Chinese market from the start.
$625 million! That is the amount Kailera Therapeutics raised in its IPO on an euphoric NASDAQ. An amount that surprised not only the
company, but also market professionals. Indeed, until a few weeks ago, the Waltham, MA-based company was planning to sell only "33 million shares," hoping at best for $459 million. But, a week before the operation, demand surged, driving the valuation to rarely reached levels (+36% compared with the previously already very optimistic assumptions), touching the top end of the range at $16. The previous record held by Moderna, with $604 million in 2018, was easily exceeded in a period...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.
Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.
RELATED ARTICLES
ASTHMA: Néovacs (Suresnes) - Oceane convertible bonds to finance its development
To finance the research programs of its vaccine candidates in asthma and food allergy, the company founded in 1993 has raised nearly €40M in the form
CANCER VACCINES: KAHIMMUNE TACKLES THE "DARK GENOME"
Founded in late 2025, the Avignon biotech signs a scientific collaboration with Gustave Roussy to select its first vaccine candidate in digestive onco
CELLPROTHERA, POST-MYOCARDIAL INFARCTION CELL THERAPY READY TO MOVE TO PHASE 3
After positive phase 2 results in the post-myocardial infarction setting, CellProthera believes it has now assembled the key clinical, regulatory and